Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (62) 62
human necessities (62) 62
hygiene (62) 62
medical or veterinary science (62) 62
metallurgy (62) 62
preparations for medical, dental, or toilet purposes (56) 56
organic chemistry (54) 54
peptides (54) 54
specific therapeutic activity of chemical compounds ormedicinal preparations (30) 30
immunology (15) 15
biochemistry (14) 14
beer (13) 13
enzymology (13) 13
humans (13) 13
investigating or analysing materials by determining theirchemical or physical properties (13) 13
measuring (13) 13
microbiology (13) 13
mutation or genetic engineering (13) 13
physics (13) 13
spirits (13) 13
testing (13) 13
vinegar (13) 13
wine (13) 13
compositions thereof (12) 12
culture media (12) 12
microorganisms or enzymes (12) 12
propagating, preserving or maintaining microorganisms (12) 12
index medicus (9) 9
life sciences (9) 9
animals (8) 8
mice (8) 8
immunotherapy (7) 7
apoptosis (6) 6
cancer (6) 6
cytotoxicity (6) 6
dendritic cells (6) 6
[sdv.imm]life sciences [q-bio]/immunology (5) 5
expression (5) 5
in-vivo (5) 5
innate immunity (5) 5
mesh: animals (5) 5
mesh: mice (5) 5
cell biology (4) 4
cells, cultured (4) 4
female (4) 4
killer cells, natural - metabolism (4) 4
lymphocyte activation (4) 4
membrane proteins - genetics (4) 4
mesh: humans (4) 4
oncology (4) 4
pharmaceutical industry (4) 4
t cells (4) 4
toll-like receptor 3 (4) 4
tumor necrosis factor ligand superfamily member 14 (4) 4
tumor necrosis factor-alpha - genetics (4) 4
[ sdv.imm ] life sciences [q-bio]/immunology (3) 3
activation (3) 3
analysis (3) 3
antibodies (3) 3
biochemistry & molecular biology (3) 3
cell line (3) 3
cell line, tumor (3) 3
data processing (3) 3
dendritic cells - immunology (3) 3
dendritic cells - metabolism (3) 3
dose-response relationship, drug (3) 3
hemic and immune systems (3) 3
herpesvirus entry mediator (3) 3
immunophenotyping (3) 3
killer cells (3) 3
ligands (3) 3
lymphocytes (3) 3
male (3) 3
mesh : animals (3) 3
mesh : mice (3) 3
mesh: toll-like receptor 3 (3) 3
mice, inbred c57bl (3) 3
middle aged (3) 3
multidisciplinary sciences (3) 3
natural killer cells (3) 3
natural sciences (3) 3
natural-killer-cells (3) 3
naturvetenskap (3) 3
proteins (3) 3
recognition (3) 3
research article (3) 3
rna (3) 3
t-cells (3) 3
toll-like receptor 3 - metabolism (3) 3
toll-like receptor-3 (3) 3
toll-like receptors (3) 3
tumor (3) 3
tumors (3) 3
virus diseases (3) 3
abridged index medicus (2) 2
adult (2) 2
aged (2) 2
aminoquinolines - pharmacology (2) 2
antigens (2) 2
antineoplastic agents (2) 2
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (111) 111
French (32) 32
German (11) 11
Danish (4) 4
Spanish (2) 2
Chinese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Harnessing innate immunity in cancer therapy
by Demaria, O and Cornen, S and Daeron, M and Morel, Y and Medzhitov, R and Vivier, E
NATURE, ISSN 0028-0836, 10/2019, Volume 574, Issue 7776, pp. 45 - 56
New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell... 
DOSE-ESCALATION | METASTATIC MELANOMA | NATURAL-KILLER-CELLS | CYCLIC GMP-AMP | COLONY-STIMULATING FACTOR | DENDRITIC CELLS | MULTIDISCIPLINARY SCIENCES | INDOLEAMINE 2,3-DIOXYGENASE | REGULATORY T-CELLS | TUMOR-GROWTH | I INTERFERON | Care and treatment | Forecasts and trends | Immunotherapy | Cancer | DNA damage | Antibodies | Cytotoxicity | Innate immunity | Lymphocytes T | Genomes | Metastasis | Cancer therapies | Immunity | Pathways | Lymphocytes | Tumor necrosis factor-TNF | Deoxyribonucleic acid--DNA | Antigens | Immunoglobulins | Dendritic cells | Immunomodulation | Melanoma | Immune checkpoint | Ligands | Bispecific antibodies | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Identification, Activation, and Selective in vivo Ablation of Mouse NK Cells via NKp46
by Thierry Walzer and Mathieu Bléry and Julie Chaix and Nicolas Fuseri and Lionel Chasson and Scott H. Robbins and Sébastien Jaeger and Pascale André and Laurent Gauthier and Laurent Daniel and Karine Chemin and Yannis Morel and Marc Dalod and Jean Imbert and Michel Pierres and Alessandro Moretta and François Romagné and Eric Vivier
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2007, Volume 104, Issue 9, pp. 3384 - 3389
Natural killer (NK) cells contribute to a variety of innate immune responses to viruses, tumors and allogeneic cells. However, our understanding of NK cell... 
T lymphocytes | Spleen cells | Natural killer T cells | Transgenic animals | B lymphocytes | Liver | Antibodies | Mice | Natural killer cells | Cells | Genetic models | Innate immunity | ALLOREACTIVITY | DENDRITIC CELLS | MOLECULE | MULTIDISCIPLINARY SCIENCES | NATURAL-KILLER-CELL | genetic models | MEDIATED CYTOLYSIS | innate immunity | INFECTION | DIFFERENTIATION | RECEPTORS | CYTOTOXICITY | T-CELLS | Green Fluorescent Proteins - metabolism | Natural Cytotoxicity Triggering Receptor 1 | Antigens, Ly | Membrane Glycoproteins - metabolism | Gene Expression Regulation - immunology | Immunophenotyping | Mice, Transgenic | Diphtheria Toxin - toxicity | Promoter Regions, Genetic - genetics | Haplorhini | Membrane Glycoproteins - genetics | Cell Differentiation - immunology | Killer Cells, Natural - cytology | Animals | Flow Cytometry | Killer Cells, Natural - drug effects | Killer Cells, Natural - metabolism | Receptors, Immunologic - genetics | Microscopy, Fluorescence | Receptors, Immunologic - metabolism | Killer cells | Immune response | Genetic aspects | Research | Cell transformation | Identification and classification | Promoter Regions (Genetics) | Green Fluorescent Proteins | Killer Cells, Natural | Gene Expression Regulation | Life Sciences | Immunology | Receptors, Immunologic | Diphtheria Toxin | Cell Differentiation | Membrane Glycoproteins | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
by André, Pascale and Denis, Caroline and Soulas, Caroline and Bourbon-Caillet, Clarisse and Lopez, Julie and Arnoux, Thomas and Bléry, Mathieu and Bonnafous, Cécile and Gauthier, Laurent and Morel, Ariane and Morel, Yannis and Rossi, Benjamin and Remark, Romain and Breso, Violette and Bonnet, Elodie and Habif, Guillaume and Guia, Sophie and Lalanne, Ana Ines and Hoffmann, Caroline and Lantz, Olivier and Fayette, Jérôme and Boyer-Chammard, Agnès and Zerbib, Robert and Dodion, Pierre and Ghadially, Hormas and Jure-Kunkel, Maria and Herbst, Ronald and Narni-Mancinelli, Emilie and Cohen, Roger B and Vivier, Eric
Cell, ISSN 0092-8674, 12/2018, Volume 175, Issue 7, pp. 1731 - 1743.e13
Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that... 
natural killer cells | CD8+ T cells | lymphocytes | cancer immunotherapy | inhibitory receptors | therapeutic monoclonal antibodies | immunce checkpoint inhibitor | CD8 | T cells | CD8(+) T cells | CETUXIMAB | EFFICACY | IMMUNOTHERAPY | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACTIVATING RECEPTORS | CD94/NKG2A | DIFFERENTIAL REGULATION | CANCER | EXPRESSION | HLA-E | LYMPHOCYTES | CELL BIOLOGY | Prevention | Fc receptors | Squamous cell carcinoma | Killer cells | Immunotherapy | Resveratrol | Monoclonal antibodies | Cancer | Life Sciences | Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells
by Friboulet, Luc and Gourzones, Claire and Tsao, Sai W and Morel, Yannis and Paturel, Carine and Témam, Stéphane and Uzan, Catherine and Busson, Pierre
BMC Cancer, ISSN 1471-2407, 06/2010, Volume 10, Issue 1, pp. 327 - 327
Background: There is increasing evidence that the toll-like receptor 3 (TLR3) is an interesting target for anti-cancer therapy. Unfortunately, most laboratory... 
TOLL-LIKE RECEPTOR-3 | TARGET | CASPASE-8 ACTIVATION | KAPPA-B ACTIVATION | NASOPHARYNGEAL CARCINOMAS | RNA | ONCOLOGY | ALPHA-DEPENDENT APOPTOSIS | TUMOR | RIP1 | CIAP2 | Neoplasms - metabolism | Up-Regulation | Apoptosis - drug effects | Inhibitor of Apoptosis Proteins - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Baculoviral IAP Repeat-Containing 3 Protein | RNA, Messenger - metabolism | Adaptor Proteins, Vesicular Transport - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Neoplasms - genetics | RNA Interference | Time Factors | Inhibitor of Apoptosis Proteins - antagonists & inhibitors | Adult | Female | Inhibitor of Apoptosis Proteins - metabolism | Tumor Cells, Cultured | Poly I-C - pharmacology | Toll-Like Receptor 3 - agonists | Toll-Like Receptor 3 - metabolism | Ubiquitin-Protein Ligases | Cell Line, Tumor | Cell Proliferation - drug effects | Neoplasms - pathology | Cellular proteins | Care and treatment | Physiological aspects | Genetic aspects | Research | Health aspects | Apoptosis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists
by Rajagopal, Deepa and Paturel, Carine and Morel, Yannis and Uematsu, Satoshi and Akira, Shizuo and Diebold, Sandra S
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 10, pp. 1949 - 1957
There is a high demand for the development of adjuvants that induce cytotoxic T lymphocytes, which are crucial for the elimination of intracellular pathogens... 
VACCINE DEVELOPMENT | ACTIVATION | TLR7 | INDUCTION | IMMUNE-RESPONSE MODIFIER | HEMATOLOGY | CARCINOMA | CD8(+) T-CELLS | CPG ODN | IMMUNOMODULATORS IMIQUIMOD | INNATE IMMUNITY | Adjuvants, Immunologic - pharmacology | Cancer Vaccines - pharmacology | Dendritic Cells - immunology | Melanoma, Experimental - metabolism | Quinolines - pharmacology | Dose-Response Relationship, Drug | Melanoma, Experimental - immunology | Interferon Type I - metabolism | Antineoplastic Agents - pharmacology | Interferon Type I - physiology | Receptor, Interferon alpha-beta - genetics | Imidazoles - therapeutic use | Tumor Cells, Cultured | Aminoquinolines - pharmacology | Dendritic Cells - metabolism | Toll-Like Receptor 7 - agonists | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Membrane Glycoproteins - agonists | Imidazoles - pharmacology | Mice, Knockout | Animals | RNA - pharmacology | Mice | Aminoquinolines - therapeutic use | Immunobiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Desirable cell death during anticancer chemotherapy
by Locher, Clara and Conforti, Rosa and Aymeric, Laetitia and Ma, Yuting and Yamazaki, Takahiro and Rusakiewicz, Sylvie and Tesnière, Antoine and Ghiringhelli, François and Apetoh, Lionel and Morel, Yannis and Girard, Jean‐Philippe and Kroemer, Guido and Zitvogel, Laurence
Annals of the New York Academy of Sciences, ISSN 0077-8923, 10/2010, Volume 1209, Issue 1, pp. 99 - 108
The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell‐death modality. This... 
cancer | chemotherapy | toll‐like receptor | immunogenic cell death | immunotherapy | Chemotherapy | Immunotherapy | Immunogenic cell death | Toll-like receptor | Cancer | CANCER-CELLS | NKT CELLS | STEM-CELLS | DENDRITIC CELLS | CYTOKINE | IMMUNOLOGY | IL-33 | CELL BIOLOGY | CALRETICULIN EXPOSURE | TOLL-LIKE RECEPTORS | toll-like receptor | T-CELLS | INNATE IMMUNITY | Animals | Apoptosis - drug effects | Neoplasms - immunology | Cancer Vaccines - administration & dosage | Humans | Antineoplastic Agents - pharmacology | Combined Modality Therapy | Mice | Neoplasms - pathology | Neoplasms - drug therapy | Antimitotic agents | Dendritic cells | Cell death | Biochemistry | T cells | Antineoplastic agents | Antigens | Medical research | T cell receptors | Apoptosis | Antigen presentation | Antitumor agents | Immunogenicity | Adjuvants | Cytotoxicity | Lymphocytes T | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
by Perrot, Ivan and Michaud, Henri-Alexandre and Giraudon-Paoli, Marc and Augier, Séverine and Docquier, Aurélie and Gros, Laurent and Courtois, Rachel and Déjou, Cécile and Jecko, Diana and Becquart, Ondine and Rispaud-Blanc, Hélène and Gauthier, Laurent and Rossi, Benjamin and Chanteux, Stéphanie and Gourdin, Nicolas and Amigues, Beatrice and Roussel, Alain and Bensussan, Armand and Eliaou, Jean-François and Bastid, Jérémy and Romagné, François and Morel, Yannis and Narni-Mancinelli, Emilie and Vivier, Eric and Paturel, Carine and Bonnefoy, Nathalie
Cell Reports, ISSN 2211-1247, 05/2019, Volume 27, Issue 8, pp. 2411 - 2425.e9
Immune checkpoint inhibitors have revolutionized cancer treatment. However, many cancers are resistant to ICIs, and the targeting of additional inhibitory... 
CD73 | CD39 | cancer immunotherapies | tumor micro-environment | immunosuppression | therapeutic antibodies | adenosine pathway | CELL EXHAUSTION | INHIBITION | RECEPTORS | EXPRESSION | THERAPEUTIC ANTIBODY | CELL BIOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma
by Viey, Emilie and Fromont, Gaëlle and Escudier, Bernard and Morel, Yannis and Da Rocha, Sylvie and Chouaib, Salem and Caignard, Anne
Journal of Immunology, ISSN 0022-1767, 02/2005, Volume 174, Issue 3, pp. 1338 - 1347
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract 2713: Preclinical development of first-in-class antibodies targeting Siglec-9 immune checkpoint for cancer immunotherapy
by Bénac, Olivier and Gaudin, Marion and Ors, Mélody and Roy, Aude Le and Blanc, Hélène Rispaud and Soulas, Caroline and Chanteux, Stéphanie and Rossi, Benjamin and Gauthier, Laurent and Paturel, Carine and Morel, Yannis and Perrot, Ivan and Cornen, Stéphanie
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 2713 - 2713
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides
by Diebold, Sandra S and Massacrier, Catherine and Akira, Shizuo and Paturel, Carine and Morel, Yannis and Reis e Sousa, Caetano
European Journal of Immunology, ISSN 0014-2980, 12/2006, Volume 36, Issue 12, pp. 3256 - 3267
Toll‐like receptor 7 (TLR7) mediates innate responses by responding to viral RNA in endocytic compartments. However, the molecular pattern recognised by TLR7... 
Dendritic cells | RNA | TLR7 | DOUBLE-STRANDED-RNA | RECOGNITION | RIG-I | IMMUNOLOGY | I INTERFERON | PLASMACYTOID DENDRITIC CELLS | CPG MOTIFS | dendritic cells | IMMUNE-SYSTEM | TOLL-LIKE RECEPTOR-9 | BACTERIAL-DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
by Oumata, Nassima and Nguyen, Phu hai and Beringue, Vincent and Soubigou, Flavie and Pang, Yanhong and Desban, Nathalie and Massacrier, Catherine and Morel, Yannis and Paturel, Carine and Contesse, Marie-Astrid and Bouaziz, Serge and Sanyal, Suparna and Galons, Hervé and Blondel, Marc and Voisset, Cécile and Teknisk-naturvetenskapliga vetenskapsområdet and Struktur- och molekylärbiologi and Biologiska sektionen and Uppsala universitet and Institutionen för cell- och molekylärbiologi
PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, p. e72112
Using a yeast-based assay, a previously unsuspected antiprion activity was found for imiquimod (IQ), a potent Toll-like receptor 7 (TLR7) agonist already used... 
SCREENING ASSAY | PROTEIN-FOLDING ACTIVITY | MAMMALIAN PRIONS | YEAST-BASED ASSAY | SCRAPIE AGENT | MULTIDISCIPLINARY SCIENCES | 23S RIBOSOMAL-RNA | IN-VIVO | DRUGS | NEURODEGENERATIVE DISEASES | 5-PERCENT CREAM | Aminoquinolines - chemical synthesis | Membrane Glycoproteins - metabolism | Humans | Saccharomyces cerevisiae - drug effects | Structure-Activity Relationship | PrPSc Proteins - metabolism | Saccharomyces cerevisiae - metabolism | Drug Evaluation, Preclinical | Aminoquinolines - pharmacology | Toll-Like Receptor 8 - agonists | Guanosine - analogs & derivatives | Toll-Like Receptor 7 - agonists | Cell Line | Glutathione Peroxidase - metabolism | Prions - metabolism | Prion Diseases - drug therapy | Toll-Like Receptor 7 - metabolism | Membrane Glycoproteins - agonists | Imidazoles - pharmacology | Peptide Termination Factors - metabolism | Protein Folding | Animals | Saccharomyces cerevisiae Proteins - metabolism | Guanosine - pharmacology | Mice | Prion Diseases - metabolism | Toll-Like Receptor 8 - metabolism | Medicine, Experimental | Medical research | Genetic engineering | Imiquimod | Analysis | TLR7 protein | Yeast | Propagation | Intelligence | Disease | Therapeutic applications | Transgenic mice | Derivatives | Mammals | Proteins | E coli | Protein folding | Prions | Toll-like receptors | Molecular biology | Prion protein | Immune system | Guanosine | Biochemistry, Molecular Biology | Toll-Like Receptor 7 | Toll-Like Receptor 8 | Life Sciences | Prion Diseases | Glutathione Peroxidase | Imidazoles | PrPSc Proteins | Peptide Termination Factors | Saccharomyces cerevisiae Proteins | Biomolecules | Membrane Glycoproteins | Saccharomyces cerevisiae | Aminoquinolines | Naturvetenskap | Natural Sciences | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Abstract 2342: NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1PD-L1 inhibitors in a preclinical model
by Sola, Caroline and Arnoux, Thomas and Chanuc, Fabien and Fuseri, Nicolas and Rossi, Benjamin and Gauthier, Laurent and Leget, Corinne and Bonnafous, Ccile and Wagtmann, Nicolai and Morel, Yannis and Andr., Pascale
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14_Supplement, pp. 2342 - 2342
Monalizumab (IPH2201) is a novel, first-in-class humanized IgG4 targeting the immune checkpoint receptor NKG2A (Natural Killer Group 2A). NKG2A is expressed as... 
Journal Article
Details down arrow
13. Full Text Abstract 2342: NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model
by Sola, Caroline and Arnoux, Thomas and Chanuc, Fabien and Fuseri, Nicolas and Rossi, Benjamin and Gauthier, Laurent and Leget, Corinne and Bonnafous, Cécile and Wagtmann, Nicolai and Morel, Yannis and André, Pascale
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2342 - 2342
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab
by Sola, Caroline and Blery, Mathieu and Bonnafous, Cécile and Bonnet, Elodie and Fuseri, Nicolas and Graziano, Robert F and Morel, Yannis and André, Pascale
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4711 - 4711
Abstract Tumor cells that express reduced levels of Major Histocompatibility Complex (MHC) class I molecules may be recognized and killed by Natural Killer... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights